Refine Search
(0)
(0)
(2)
(3)

Thrombotic Diseases

The reports provide a detailed assessment of current treatment paradigms, primary research-based analysis of the dynamics driving treatment choices, competitive evaluation of marketed drugs and the late-stage development pipeline, discussion of the level of opportunity today and in 10 years, and estimated current and future market value.

Acute Ischemic Stroke: Global Drug Forecast and Market Analysis to 2027

  • $10,995
  • July 2018
Add to Basket Quick View Add to Saved List

Stroke is caused by the interruption of the blood supply to the brain, usually because a cerebral blood vessel ruptures and bleeds (hemorrhagic stroke) or is blocked by a clot (ischemic stroke), which obstructs blood flow and oxygen and nutrien...

Acute Coronary Syndrome: Competitive Landscape to 2026

  • $3,495
  • June 2018
Add to Basket Quick View Add to Saved List

Acute coronary syndrome (ACS) refers to a spectrum of myocardial ischemic states caused by the disruption of atherosclerotic plaques in the coronary arteries. The syndrome is precipitated by coronary artery occlusion (stenosis), which results i...

PharmaPoint: Venous Thromboembolism - Global Drug Forecast and Market Analysis to 2026

  • $10,995
  • June 2017
Add to Basket Quick View Add to Saved List

Venous thromboembolism (VTE) is a disease that includes a myriad of life-threatening disorders ranging from pulmonary embolism (PE) to deep vein thrombosis (DVT. The condition is relatively prevalent and is associated with long-term mortality a...

PharmaPoint: Atrial Fibrillation – Global Drug Forecast and Market Analysis to 2025

  • $10,995
  • August 2016
Add to Basket Quick View Add to Saved List

Atrial fibrillation (AF) is the most common cardiac arrhythmia and is a heart condition that causes an irregular and often abnormally fast heart rate. Various therapeutic options are available to treat patients with AF, and most patients will r...

Join our mailing list
Find out first about the latest reports and offers.